Cervical Cancer Market Production Growth and Industry Analysis to 2025
According to a new report published by Reports Monitor titled, “THE GLOBAL CERVICAL CANCER TREATMENT MARKET, GROWTH OPPORTUNITIES AND FORECAST TILL 2025” the global Cervical Cancer marketwas valued at XX million in 2018, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2018 to 2025.
The lower part of uterus that connects to vagina is cervix. Cervical cancer develops in the cells of the cervix. Strains of Human Papillomavirus (HPV), generally a sexually transmitted antigen, are the general cause of cervical cancer. The disease begins when healthy cells acquire mutation leading to the uncontrolled growth of cells. These cells form a tumor which invades the nearby tissues. There are different types of cervical cancer such as Squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas. Squamous cell carcinomas develop from cells in the exocervix while adenocarcinomas develop from gland cells. There are different methods for treatment of cervical cancer; cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, and trachelectomy are some of the commonly used treatment. The major driver of cervical cancer treatment market is increase in prevalence of cervical cancer and growing awareness of cervical cancer in women. As per WHO, cervical cancer accounts for 3.7% of all the cancers. In 2012, 528,000 women were diagnosed with cervical cancer. However, the growing demand of early diagnosis and advancement in treatment procedures will also fuel the growth of the market. However, the high cost of treatment is a major restraint for the growth of the market. Moreover, the growing research & development in healthcare sector and increasing funding for improving medical facilities is pushing forward the market.
The cervical cancer treatment market is segmented on the basis of type, treatment, end user and region.Based on type it is further classified as squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas.On the basis of treatment the market is segmented as surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy, and others. Surgery is further sub segmented as cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, trachelectomy, and others. Radiation Therapy is further segmented into external beam radiation and brachytherapy. Chemotherapy is further segmented into cisplatin, carboplatin, paclitaxel, doxorubicin, gemcitabine, bevacizumab, and others.
Based on end user the market is segmented as hospitals, cancer cares, diagnostic centres and others.
Globally, the cervical cancer treatment market is segmented into North America, Europe, Asia pacific and LAMEA.
North America holds the largest share of market owing to their advancement in technology in field of oncology. The changing lifestyle of women in North America is increasing the patient pool in North America. As per America cancer society, U.S is expected to have more than 13000 new cervical patients this year.
Europe has the second largest market, the growth of the market is attributed to a number of healthcare institutions offering treatment of cancer and huge investments in research and development activities by the U.K. and Germany. In Germany, the market is mainly driven by an increase in the use of new technological devices for the diagnosis and treatment of cancer.
Asia pacific region is expected to have fastest growth during the forecast period. This region has several growth opportunities and the growing awareness about treatment of cervical cancer is driving the market. Additionally, countries like India and China are paying heed on early diagnosis of the disease and cost effective treatment of disease. The growing government support in healthcare of the region is also fueling the growth of the market
LAMEA has the least share of the market, although number of patient of cervical cancer is maximum in this region. Middle is the major contributor of the region as they are financially sound also African countries are taking initiatives in healthcare which will boost the market growth.
Pfizer Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc, Hetero, Biocon, Novartis, Genentech USA, ALLERGAN, Actavis Pharma Company are the key players of market.
We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.